Zelboraf Approved for Late-Stage Melanoma
The FDA today approved Zelboraf (vemurafenib) for the treatment of advanced or metastatic melanoma. The drug extends survival for the 50% of melanoma patients whose tumors carry the BRAF mutation.
Click here to read the full story.
The content has been reported and it will be reviewed by a moderator.
